The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ERCC1-associated platinum resistance and PARP inhibition in lung cancers.
H. Cheng
No relevant relationships to disclose
Z. Zhang
No relevant relationships to disclose
C. A. Powell
No relevant relationships to disclose
B. Halmos
No relevant relationships to disclose